Literature DB >> 3011440

Effects of angiotensin converting enzyme inhibitor, perindopril, on autonomic reflexes.

A A Ajayi, K R Lees, J L Reid.   

Abstract

The effect of the angiotensin converting enzyme inhibitor, perindopril, on autonomic function was assessed in a double blind, placebo controlled, crossover study in 10 normotensive males. Eight milligram of perindopril given orally lowered blood pressure without a change in heart rate. Perindopril enhanced the vagally mediated heart rate variation with deep breathing. There was no impairment of the responses to either bicycle exercise at 175 W for 5 min or isometric handgrip. The pressor response to cold was not changed and the response to the Valsalva manoeuvre was unaltered. These results suggest that the absence of tachycardia after perindopril may be in part related, as has been reported with other converting enzyme inhibitors, to enhanced cardiac parasympathetic tone. Vagomimetic action may be a property of converting enzyme inhibitors in general.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3011440     DOI: 10.1007/bf00614298

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  23 in total

Review 1.  Vasodilatation of small and large arteries in hypertension.

Authors:  J A Levenson; A C Simon; M E Safar
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

2.  The site of cardiovascular action of angiotensin II in the brain.

Authors:  M D Joy; R D Lowe
Journal:  Clin Sci       Date:  1970-08       Impact factor: 6.124

3.  Inhibition by parasympathetic nerve stimulation of the release of the adrenergic transmitter.

Authors:  K Löffelholz; E Muscholl
Journal:  Naunyn Schmiedebergs Arch Pharmakol       Date:  1970

Review 4.  Medical intelligence drug therapy: captopril.

Authors:  D G Vidt; E L Bravo; F M Fouad
Journal:  N Engl J Med       Date:  1982-01-28       Impact factor: 91.245

5.  Cardiac denervation in diabetes.

Authors:  T Wheeler; P J Watkins
Journal:  Br Med J       Date:  1973-12-08

6.  Autonomic pathways responsible for bradycardia on facial immersion.

Authors:  J P Finley; J F Bonet; M B Waxman
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1979-12

7.  Inhibition of angiotensin I-converting enzyme with S 9490: biochemical effects, interspecies differences, and role of sodium diet in hemodynamic effects.

Authors:  M Laubie; P Schiavi; M Vincent; H Schmitt
Journal:  J Cardiovasc Pharmacol       Date:  1984 Nov-Dec       Impact factor: 3.105

8.  Angiotensin-converting enzyme inhibitor resets baroreceptor reflexes in conscious dogs.

Authors:  R Hatton; D Clough; K Faulkner; J Conway
Journal:  Hypertension       Date:  1981 Nov-Dec       Impact factor: 10.190

9.  Plasma catecholamines and cardiovascular responses during converting enzyme inhibition in normotensive and hypertensive man.

Authors:  A P Niarchos; T G Pickering; A Morganti; J H Laragh
Journal:  Clin Exp Hypertens A       Date:  1982

10.  Heart rate control in hypertensive patients treated by captopril.

Authors:  A Sturani; C Chiarini; E Degliesposti; A Santoro; A Zuccalà; P Zucchelli
Journal:  Br J Clin Pharmacol       Date:  1982-12       Impact factor: 4.335

View more
  15 in total

Review 1.  Newer ACE inhibitors. A look at the future.

Authors:  A Salvetti
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

2.  Effects of the angiotensin converting enzyme inhibitor, benazepril, on the sino-aortic baroreceptor heart rate reflex.

Authors:  J N West; P C Champion de Crespigny; T J Stallard; W A Littler
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727

Review 3.  Perindopril. A review of its pharmacokinetics and clinical pharmacology.

Authors:  R J Macfadyen; K R Lees; J L Reid
Journal:  Drugs       Date:  1990       Impact factor: 9.546

4.  Clinical acceptability of ACE inhibitor therapy in mild to moderate hypertension, a comparison between perindopril and enalapril.

Authors:  L Alcocer; C Campos; J H Bahena; A Nacaud; J Parra Carillo; C Calvo; C Weber; G Lerebours; L Mickalonis; M T Villahermosa
Journal:  Cardiovasc Drugs Ther       Date:  1995-06       Impact factor: 3.727

5.  The haemodynamic and humoral effects of treatment for one month with the angiotensin converting enzyme inhibitor perindopril in salt replete hypertensive patients.

Authors:  K R Lees; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  Haemodynamic and humoral effects of oral perindopril, an angiotensin converting enzyme inhibitor, in man.

Authors:  K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1987-02       Impact factor: 4.335

Review 7.  Perindopril. A review of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  P A Todd; A Fitton
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

8.  The pharmacokinetics and pharmacodynamics of perindopril in patients with hepatic cirrhosis.

Authors:  H H Tsai; K R Lees; C W Howden; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1989-07       Impact factor: 4.335

9.  Converting-enzyme inhibition buffers the counter-regulatory response to acute administration of nicardipine.

Authors:  M Bellet; P Sassano; T Guyenne; P Corvol; J Menard
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

10.  Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br Heart J       Date:  1991-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.